



## *Manufacturer's Information*

# **Test No. 23-5805: DNA-Blood**

---

Each sample set consisted of two known bloodstains on FTA™ Micro Cards (Items 1 and 2), and two questioned stains on colored fabric (Items 3 and 4). Participants were requested to analyze these items using their existing protocols.

**SAMPLE PREPARATION:** The stains on Items 1 - 4 were prepared using human whole blood which was either drawn into citric acid preservative bags or EDTA tubes. Item 1 (75  $\mu$ L) and Item 4 (50  $\mu$ L) were created using blood from the same female donor. Item 2 (75  $\mu$ L) and Item 3 (50  $\mu$ L) were created using blood from the same male donor. Stains from different sources were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on September 06, 2023 following completion of the verification stage.

**SAMPLE SET ASSEMBLY:** For each sample set, all Items (1-4) were packaged into separate envelopes and then placed together in a pre-labeled sample set envelope and sealed. The sealed sample set envelopes were then packaged in pre-labeled heat seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

**VERIFICATION:** All predistribution laboratories confirmed the manufacturer's expected associations. Consistent allelic results were reported for all STR and YSTR loci.

*The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the results that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.*

*Manufacturer's Information, continued*

**Test No. 23-5805: DNA-Blood**

<b>Amelogenin and STR Results</b>						
<i>Results compiled from predistribution laboratories and a consensus of at least 10 participants.</i>						
<b>Item</b>	<b>D1S1656</b>	<b>D2S1338</b>	<b>D2S441</b>	<b>D3S1358</b>	<b>D5S818</b>	<b>D6S1043</b>
	<b>D7S820</b>	<b>D8S1179</b>	<b>D10S1248</b>	<b>D12S391</b>	<b>D13S317</b>	<b>D16S539</b>
	<b>D18S51</b>	<b>D19S433</b>	<b>D21S11</b>	<b>D22S1045</b>	<b>Amelogenin</b>	<b>CSF1PO</b>
	<b>FGA</b>	<b>Penta D</b>	<b>Penta E</b>	<b>SE33</b>	<b>TH01</b>	<b>TPOX</b>
	<b>vWA</b>	<b>DYS391</b>	<b>DYS570</b>	<b>DYS576</b>	<b>Y Indel</b>	
1	16,16.3	17,25	10,11	14,17	10,11	17,19
	10,11	11,13	14,17	17.3,25	11,12	9,11
	17,19	14,14	29,30	16,17	X,X	12,12
	23,26	10,11	7,21	17.2,26.2	6,9	11,12
	18,18	NM	NM	NM	NM	
2	14,15	17,25	11,14	15,17	8,12	12,15
	10,11	14,16	12,13	16,19	11,14	9,11
	16,17	11,12	28,31	11,17	X,Y	10,12
	23,24	9,11	10,13	16,18	8,9.3	8,11
	14,17	10	19	15	2	
3	14,15	17,25	11,14	15,17	8,12	12,15
	10,11	14,16	12,13	16,19	11,14	9,11
	16,17	11,12	28,31	11,17	X,Y	10,12
	23,24	9,11	10,13	16,18	8,9.3	8,11
	14,17	10	19	15	2	
4	16,16.3	17,25	10,11	14,17	10,11	17,19
	10,11	11,13	14,17	17.3,25	11,12	9,11
	17,19	14,14	29,30	16,17	X,X	12,12
	23,26	10,11	7,21	17.2,26.2	6,9	11,12
	18,18	NM	NM	NM	NM	

<b>YSTR Results</b>									
<i>Results compiled from predistribution laboratories and a consensus of at least 10 participants.</i>									
<b>Item</b>	<b>DYF387S1</b>	<b>DYS19</b>	<b>DYS385</b>	<b>DYS389-I</b>	<b>DYS389-II</b>	<b>DYS390</b>	<b>DYS391</b>	<b>DYS392</b>	<b>DYS393</b>
	<b>DYS437</b>	<b>DYS438</b>	<b>DYS439</b>	<b>DYS448</b>	<b>DYS449</b>	<b>DYS456</b>	<b>DYS458</b>	<b>DYS460</b>	<b>DYS481</b>
	<b>DYS518</b>	<b>DYS533</b>	<b>DYS549</b>	<b>DYS570</b>	<b>DYS576</b>	<b>DYS627</b>	<b>DYS635</b>	<b>DYS643</b>	<b>YGATAH4</b>
2	36,38	15	15,18	13	31	21	10	11	13
	14	11	11	21	>40#	15	16	10	27
	39	12	11	19	15	20	21	13	12
3	36,38	15	15,18	13	31	21	10	11	13
	14	11	11	21	*	15	16	10	27
	39	12	11	19	15	20	21	13	12

\* Results were not received by a minimum of 10 participants for the loci indicated.

NM - Non-Male profile, YSTR results not expected.

# - Approximately 15% of participants reported ">41"

*The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the results that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.*